Comparable stake leader
Ron Bentsur
SEC ownership of Nuvectis Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001875558.
Disclosed value leader
Ron Bentsur
Comparable rows
0/50
Latest evidence
30 Jun 2026
- Public ticker
- NVCT on Nasdaq
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ron Bentsur
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001875558
- Issuer location
- Fort Lee, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nuvectis Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ron Bentsur
Disclosed value leader
Ron Bentsur
Comparable rows
0/50
Latest evidence
30 Jun 2026
3/4/5
13F
Highest disclosed value: $73,768,480
50 rows are not safely comparable across share classes.
Showing 1-8 of 50 holder rows.
Quick read
Ron Bentsur has the largest disclosed position value at $73.77M.
0 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ron Bentsur's linked filing trail.
Disclosed position value
Top 5
Ron Bentsur
$73.77M
Marlio Charles Mosseri
$59.22M
Enrique Poradosu
$13.64M
Shay Shemesh
$13.54M
BlackRock, Inc.
$5.91M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ron Bentsur |
3/4/5
Chairman & CEO, Director, 10%+ Owner
|
—
class O/S missing
|
$73,768,480
3,688,424 shares
|
+$278,600 | 30 Jun 2026 |
| Marlio Charles Mosseri |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$59,223,123
3,295,897 shares
|
+$1,873,083 | 30 Jun 2026 |
| Enrique Poradosu |
3/4/5
Chief Science & Business Off
|
—
class O/S missing
|
$13,637,527
1,806,319 shares
|
— | 06 Jan 2026 |
| Shay Shemesh |
3/4/5
Chief Dev. & Ops. Officer
|
—
class O/S missing
|
$13,537,484
1,793,068 shares
|
— | 06 Jan 2026 |
| BlackRock, Inc. |
13F
Company
|
—
class O/S missing
|
$5,909,128
764,441 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$5,100,865
659,879 shares
|
— | 31 Mar 2026 |
| IRIDIAN ASSET MANAGEMENT LLC/CT |
13F
Company
|
—
class O/S missing
|
$5,038,082
651,757 shares
|
— | 31 Mar 2026 |
| Occam Crest Management LP |
13F
Company
|
—
class O/S missing
|
$3,147,246
407,147 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$2,291,193.
Buys
$2,291,193
Insiders: 4
Sells
$0
Insiders: 0
Net
+$2,291,193
Shares: +246,270
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 246,270
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 62,500 | 0 | $1,166,000 | $0 | +$1,166,000 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 183,770 | 0 | $1,125,193 | $0 | +$1,125,193 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Nuvectis Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Ron Bentsur
Net 12M change
+$2,291,193
Latest report
30 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ron Bentsur | Chairman & CEO, Director, 10%+ Owner | $73,768,480 | +$278,600 | +0.38% | Filing P/S | 30 Jun 2026 |
| Marlio Charles Mosseri | 10%+ Owner | $59,223,123 | +$1,873,083 | +3.3% | Mixed | 30 Jun 2026 |
| Enrique Poradosu | Chief Science & Business Off | $13,637,527 | Mixed | 06 Jan 2026 | ||
| Shay Shemesh | Chief Dev. & Ops. Officer | $13,537,484 | Mixed | 06 Jan 2026 | ||
| Michael J. Carson | Vice President, Finance | $1,510,870 | Mixed | 06 Jan 2026 | ||
| Kenneth Hoberman | Director | $1,299,722 | Median | 11 Jun 2026 | ||
| Matthew L. Kaplan | Director | $1,234,944 | +$64,240 | +5.5% | Median | 11 Jun 2026 |
| James F. Oliviero III | Director | $949,460 | Median | 11 Jun 2026 | ||
| Juan Sanchez | Director | $879,634 | +$75,270 | +9.4% | Median | 11 Jun 2026 |
| Uri Ben-Or | Int. Principal Financial Off. | $283,471 | Mixed | 08 Feb 2022 |
Recent insider transactions for Nuvectis Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Marlio Charles Mosseri | NVCT | Common Stock | Purchase | 1.59% | $916,000 | $18.32 | 50,000 | 3,186,576 | 30 Jun 2026 | By Emerald Hill Ventures SARL SPF. |
| Ron Bentsur | NVCT | Common Stock | Purchase | 0.34% | $250,000 | $20.00 | 12,500 | 3,688,424 | 30 Jun 2026 | Direct |
| Kenneth Hoberman | NVCT | Common Stock | Award | 26.3% | 35,000 | 168,140 | 11 Jun 2026 | Direct | ||
| James F. Oliviero III | NVCT | Common Stock | Award | 39.8% | 35,000 | 122,828 | 11 Jun 2026 | Direct | ||
| Juan Sanchez | NVCT | Common Stock | Award | 44.6% | 35,000 | 113,380 | 11 Jun 2026 | Direct | ||
| Matthew L. Kaplan | NVCT | Common Stock | Award | 28% | 35,000 | 159,760 | 11 Jun 2026 | Direct | ||
| Shay Shemesh | NVCT | Common Stock | Award | 9.13% | 150,000 | 1,793,068 | 06 Jan 2026 | Direct | ||
| Ron Bentsur | NVCT | Common Stock | Award | 4.25% | 150,000 | 3,675,924 | 06 Jan 2026 | Direct | ||
| Enrique Poradosu | NVCT | Common Stock | Award | 9.06% | 150,000 | 1,806,319 | 06 Jan 2026 | Direct | ||
| Michael J. Carson | NVCT | Common Stock | Award | 44% | 61,200 | 200,118 | 06 Jan 2026 | Direct | ||
| Juan Sanchez | NVCT | Common Stock | Purchase | 20% | $75,270 | $5.79 | 13,000 | 78,150 | 05 Nov 2025 | Direct |
| Matthew L. Kaplan | NVCT | Common Stock | Purchase | 9.67% | $64,240 | $5.84 | 11,000 | 124,760 | 05 Nov 2025 | Direct |
| Ron Bentsur | NVCT | Common Stock | Purchase | 0.14% | $28,600 | $5.72 | 5,000 | 3,525,924 | 05 Nov 2025 | Direct |
| Marlio Charles Mosseri | NVCT | Common Stock | Purchase | 2.38% | $457,410 | $6.28 | 72,836 | 3,136,576 | 27 Oct 2025 | By Emerald Hill Ventures SARL SPF. |
| Marlio Charles Mosseri | NVCT | Common Stock | Purchase | 1.16% | $215,459 | $6.15 | 35,034 | 3,063,740 | 24 Oct 2025 | By Emerald Hill Ventures SARL SPF. |
| Marlio Charles Mosseri | NVCT | Common Stock | Purchase | 1.57% | $284,214 | $6.06 | 46,900 | 3,028,706 | 23 Oct 2025 | By Emerald Hill Ventures SARL SPF. |
| Juan Sanchez | NVCT | Common Stock | Award | 85.4% | 30,000 | 65,150 | 22 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.